Preliminary clinical results of our therapeutic cancer vaccine in patients with stage IV NSCLC accepted for an oral presentation at the prestigious annual meeting of the AACR
We are delighted to announce that our abstract on the preliminary clinical results of the therapeutic cancer vaccine PDC*lung01 in patients (pts) with stage IV NSCLC was accepted for an oral presentation at the prestigious annual meeting of the American Association for Cancer Research (AACR). The meeting is taking place in April in San Diego, USA. The presentation is scheduled during the session “Cancer Vaccines: Ready for Prime Time?”.
Title of the presentation: “Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC”
Date: April 7, 2024 at 3:00 PMSession Type: Clinical Trials Mini symposium
Track(s): Clinical Trials
Session: CTMS01 - Cancer Vaccines: Ready for Prime Time?
Location: Ballroom 20 AB - Upper Level - Convention Center
About the AACR annual event
The American Association for Cancer Research is organizing the Annual Meeting for 2024, slated to occur from April 05 to 10, 2024, at the San Diego Convention Center in San Diego, California, USA.
Founded in 1907 by 11 physicians and scientists, the American Association for Cancer Research (AACR) stands as the world's oldest and largest professional association dedicated to cancer research. Headquartered in Philadelphia, AACR is committed to exploring every facet of cancer research, encompassing basic, clinical, and translational studies aimed at understanding the causes, prevention, diagnosis, and treatment of cancer. With a global presence, the organization boasts over 52,000 members across 130 countries and territories.
Drawing in over 21,000 participants worldwide, the annual meeting organized by the American Association for Cancer Research (AACR) has earned the reputation as the primary platform for sharing and deliberating on cancer-related research. This gathering provides a forum for the discussion of more than 6,000 abstracts and features over 250 invited presentations, unveiling noteworthy breakthroughs in basic, clinical, and translational cancer research. The event encompasses scientific award lectures, workshops on grant writing, networking opportunities, and educational sessions, offering a well-rounded and comprehensive program.
